Compare Eli Lilly And Co (LLY) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs United Airlines Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,173.56 (market cap $1.04T), while United Airlines Holdings Inc trades at $106.87 (market cap $34.87B). The key difference: Eli Lilly And Co is far larger — about 29.8× United Airlines Holdings Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while United Airlines Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and United Airlines Holdings Inc for 46 Days on average.
| LLY | UAL | |
|---|---|---|
Market Cap | $1.04T | $34.87B |
Volume | 3,064,878 | 6,329,678 |
Sector | Health | Industrials |
52-Week High | $1.28K | $136.11 |
52-Week Low | $799.57 | $85.21 |
Typical Hold Time | 93 Days | 46 Days |
Enterprise Value | $1.09T | $51.90B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
United Airlines (UAL) trades at $105.65, down 4.1% today, with a bearish technical signal despite recent earnings beats. The company shows solid fundamentals with revenue growth from $57.1B in 2024 to $59.1B in 2025 and net income of $3.35B. Valuation metrics appear attractive with P/E of 10.06 and P/S of 0.56. Recent news highlights aggressive customer acquisition strategies targeting Delta and American Airlines' premium travelers with status-match offers and Starlink-enabled WiFi advantages.
The investment outlook remains positive given strong analyst consensus (66% buy rating) with $158.10 price target representing 50% upside. Key risks include rising fuel costs, labor expenses, and competitive pressures. Earnings momentum continues with three consecutive quarterly beats, though Q3 2026 results will be crucial for maintaining investor confidence amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
